SecBot SecBot
SECBOTREPLAY Home › Report › NRXP

NRXP · NRx Pharmaceuticals reported Q1 2026 EPS of -$0.04, beating consensus…

NRx Pharmaceuticals, Inc. · PRESS-RELEASE filed May 18, 2026 at 07:00 ET

At the news

BULLISHIMPACT 6/10

PRESS-RELEASE filed May 18, 2026 at 07:00 ET

NRx Pharmaceuticals reported Q1 2026 EPS of -$0.04, beating consensus of -$0.13 by 69.2%, with net loss narrowing to $1.4M from $5.5M a year ago. The company advanced multiple regulatory milestones including an anticipated FDA ANDA decision on preservative-free ketamine in Q3 2026, initiated commercial manufacturing, and generated first revenue from its HOPE Therapeutics clinic network. The beat is notable for a clinical-stage biotech but driven by non-recurring fair value accounting changes rather than operational improvement.

  • EPS -$0.04 vs consensus -$0.13 (69.2% beat)
  • Net loss narrowed to $1.4M from $5.5M YoY, though operating loss widened to $4.7M from $3.8M
  • Cash and equivalents $6.7M as of March 31, 2026; raised ~$7M post-quarter via ATM
  • FDA ANDA decision on preservative-free ketamine expected Q3 2026 with favorable preliminary determinations

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access